Fig. 1From: Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathiesVariations of creatine kinase (a) and troponin (b) levels, as well as forced vital capacity (c) and diffusion lung CO capacity (d). T -12, 12 months before the start of combination treatment; T 0, start of combination treatment; T 12, 12 months after the start of combination treatmentBack to article page